298 related articles for article (PubMed ID: 29155104)
1. Treatment strategies for psoriatic arthritis.
Schemoul J; Poulain C; Claudepierre P
Joint Bone Spine; 2018 Oct; 85(5):537-544. PubMed ID: 29155104
[TBL] [Abstract][Full Text] [Related]
2. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review.
Acosta Felquer ML; Coates LC; Soriano ER; Ranza R; Espinoza LR; Helliwell PS; FitzGerald O; McHugh N; Roussou E; Mease PJ
J Rheumatol; 2014 Nov; 41(11):2277-85. PubMed ID: 25362711
[TBL] [Abstract][Full Text] [Related]
3. Updated guidelines for the management of axial disease in psoriatic arthritis.
Nash P; Lubrano E; Cauli A; Taylor WJ; Olivieri I; Gladman DD
J Rheumatol; 2014 Nov; 41(11):2286-9. PubMed ID: 25362712
[TBL] [Abstract][Full Text] [Related]
4. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis.
Coates LC; Gossec L; Ramiro S; Mease P; van der Heijde D; Smolen JS; Ritchlin C; Kavanaugh A
Rheumatology (Oxford); 2017 Aug; 56(8):1251-1253. PubMed ID: 28077693
[No Abstract] [Full Text] [Related]
5. Treatment of psoriatic arthritis: management recommendations.
Gossec L; Smolen JS
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S73-7. PubMed ID: 26471459
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: a systematic review.
Boehncke WH; Alvarez Martinez D; Solomon JA; Gottlieb AB
J Rheumatol; 2014 Nov; 41(11):2301-5. PubMed ID: 25362715
[TBL] [Abstract][Full Text] [Related]
7. Psoriatic arthritis: new evidence for old concepts.
Soriano ER; Marin J; Acosta-Felquer ML
Curr Opin Rheumatol; 2018 Jan; 30(1):87-93. PubMed ID: 29035933
[TBL] [Abstract][Full Text] [Related]
8. Psoriatic arthritis: current therapy and future approaches.
Huynh D; Kavanaugh A
Rheumatology (Oxford); 2015 Jan; 54(1):20-8. PubMed ID: 25125588
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis.
Orbai AM; Weitz J; Siegel EL; Siebert S; Savage LJ; Aydin SZ; Luime JJ; Elkayam O; Neerinckx B; Urbancek S; de Vlam K; Ritchlin CT;
J Rheumatol; 2014 Nov; 41(11):2290-4. PubMed ID: 25362713
[TBL] [Abstract][Full Text] [Related]
10. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.
Reygaerts T; Mitrovic S; Fautrel B; Gossec L
Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology.
Marchesoni A; Olivieri I; Salvarani C; Pipitone N; D'Angelo S; Mathieu A; Cauli A; Punzi L; Ramonda R; Scarpa R; Maccarone M; Lubrano E
Clin Exp Rheumatol; 2017; 35(6):991-1010. PubMed ID: 29185959
[TBL] [Abstract][Full Text] [Related]
12. A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service.
Abignano G; Fadl N; Merashli M; Vandevelde C; Freeston J; McGonagle D; Marzo-Ortega H
J Am Acad Dermatol; 2019 Jun; 80(6):1796-1798. PubMed ID: 30771422
[No Abstract] [Full Text] [Related]
13. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
14. The approach to precision medicine for the treatment of psoriatic arthritis.
Miyagawa I; Tanaka Y
Immunol Med; 2020 Sep; 43(3):98-102. PubMed ID: 32306849
[TBL] [Abstract][Full Text] [Related]
15. [Psoriatic arthritis].
Cauza E; Dunky A
Wien Med Wochenschr; 2006 Nov; 156(21-22):587-95. PubMed ID: 17160376
[TBL] [Abstract][Full Text] [Related]
16. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
[TBL] [Abstract][Full Text] [Related]
17. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
Gossec L; Coates LC; de Wit M; Kavanaugh A; Ramiro S; Mease PJ; Ritchlin CT; van der Heijde D; Smolen JS
Nat Rev Rheumatol; 2016 Dec; 12(12):743-750. PubMed ID: 27829672
[TBL] [Abstract][Full Text] [Related]
18. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
[TBL] [Abstract][Full Text] [Related]
19. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.
Raychaudhuri SP; Wilken R; Sukhov AC; Raychaudhuri SK; Maverakis E
J Autoimmun; 2017 Jan; 76():21-37. PubMed ID: 27836567
[TBL] [Abstract][Full Text] [Related]
20. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
